{"id":619215,"date":"2026-09-09T10:56:13","date_gmt":"2026-09-09T10:56:13","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/619215\/"},"modified":"2026-09-09T10:56:13","modified_gmt":"2026-09-09T10:56:13","slug":"uks-first-ai-and-robotics-organoid-facility-for-infectious-disease-rd","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/619215\/","title":{"rendered":"UK&#8217;s first AI and robotics organoid facility for infectious disease R&#038;D"},"content":{"rendered":"<p class=\"picture\"><img fetchpriority=\"high\" decoding=\"async\" alt=\"Liverpool-Accelerator-Lab-launch\" src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/09\/22572_liverpoolacceleratorlablaunch_325448.jpg\"   loading=\"eager\" class=\"lazyloaded\" width=\"2000\" height=\"1333\"\/><\/p>\n<p>A new \u00a320 million high-security robotic laboratory designed to accelerate research into deadly infections and diseases has officially opened in Liverpool.<\/p>\n<p><a href=\"https:\/\/lstmed.ac.uk\/about-us\/our-campus-and-facilities\/liverpool-accelerate-laboratory\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">The Liverpool Accelerate Laboratory<\/a> is the first facility of its kind in the UK. Developed through the <a href=\"https:\/\/www.infectioninnovation.com\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">LSTM-led iiCON: Infection Innovation Consortium<\/a> and supported by funding from the Liverpool City Region Combined Authority, it will combine <a href=\"https:\/\/www.drugtargetreview.com\/what-googles-ai-talent-exodus-could-mean-for-future-drug-discovery\/2136174.article\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">artificial intelligence<\/a>, <a href=\"https:\/\/www.drugtargetreview.com\/drug-discovery-integration-takes-centre-stage-at-slas-boston-2026\/1866703.article\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">robotics<\/a> and human <a href=\"https:\/\/www.drugtargetreview.com\/patient-derived-tumour-organoid-biobank-maps-cancer-gene-dependencies\/2136360.article\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">organoid<\/a> technology to advance the development of drugs and vaccines.<\/p>\n<p>AI and robotics meet human organoids<\/p>\n<p>The lab will allow researchers to use lab-grown human organoids to investigate infectious diseases and test potential treatments, helping the industry speed up drug discovery while reducing reliance on animal testing.<\/p>\n<p>Professor Giancarlo Biagini, Pro Vice-Chancellor for Research and Innovation at Liverpool School of Tropical Medicine, said: \u201cThe Liverpool Accelerate Laboratory is an advanced facility that builds on years of pioneering organoid research at LSTM and partner organisations.<\/p>\n<p>\u201cIt harnesses the potential held by this exciting technology to accelerate the development of advanced human infection models for emerging and high-consequence diseases.<\/p>\n<p>\u201cBy incorporating machine learning, AI and robotics in a highly secure Category 3 facility, we are automating the development and commercialisation of these advanced organoid models, to expand the scale and speed of infectious disease research and development while delivering precision and reproducibility.\u201d<\/p>\n<p>According to Professor Janet Hemingway, founding director of iiCON,\u00a0the development of advanced organoid models could support commercial innovation and accelerate the discovery of a new generation of drugs and vaccines. The facility would also strengthen Liverpool\u2019s position as a global hub for infection research, while supporting industry, creating high-value jobs and delivering benefits for patients, communities and the wider economy.<\/p>\n<p>&#13;<\/p>\n<p>Research using human organoids is at the cutting-edge of infection research and development (R&amp;D) \u2013 moving drug discovery away from animal testing and offering new ways of shaping more targeted treatments to respond to some of our most challenging infections.\u201d<\/p>\n<p>&#13;<\/p>\n<p class=\"quotesource\">Professor Janet Hemingway, Founding Director of iiCON<\/p>\n<p>&#13;<\/p>\n<p>High-security research at scale<\/p>\n<p>The Category 3 laboratory will enable scientists to work with high-consequence pathogens including salmonella and tuberculosis. Automated systems will allow researchers to study how these infections affect organoids and assess the potential effectiveness of new treatments in humans.<\/p>\n<p>Claire Caygill, a post-doctoral research assistant involved in integrating robotics and biology at the facility, said: \u201cThe amount of data the robotics will be able to capture is way beyond what we would be capable of so this is going to be an exciting new challenge for us.<\/p>\n<p>\u201cWe now have the capacity to work on high-consequence pathogens without needing a human interface, so it takes away the risk for lab workers while allowing us to do experiments at scale and at speed.\u201d<\/p>\n<p>The steel-clad facility is also designed to meet forthcoming changes to the Terrorism Act and is intended to become an important UK biosecurity asset.<\/p>\n<p>Boost for Liverpool\u2019s life sciences sector<\/p>\n<p>The facility is due to open fully in 2027 and is expected to create well-paid jobs and generate \u00a340 million in investment during its first three years.<\/p>\n<p>Open to businesses of all sizes, the laboratory\u00a0will support initial pilot research to allow companies to test new approaches using organoid experiments,\u00a0with SMEs and start-ups developing new drugs and vaccines expected to benefit in particular.<\/p>\n<p>Liverpool City Region Mayor Steve Rotheram said: \u201cLiverpool has been leading the fight against infectious diseases for generations and this new facility will help keep us at the cutting edge.<\/p>\n<p>\u201cWe\u2019re bringing together AI, robotics and world-class research in one place, which means we can develop new drugs and vaccines faster, save lives and reduce the need for animal testing.<\/p>\n<p>\u201cThis is exactly the kind of investment our Life Sciences Innovation Zone was designed to deliver, creating good jobs, attracting further investment and cementing our position as a global leader in infection innovation.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"A new \u00a320 million high-security robotic laboratory designed to accelerate research into deadly infections and diseases has officially&hellip;\n","protected":false},"author":2,"featured_media":619216,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-619215","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/619215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=619215"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/619215\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/619216"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=619215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=619215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=619215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}